Raleigh, United States
D2V Clinical, founded in 2019, stands at the forefront of biopharmaceutical development, particularly in oncology, hematology, and rare diseases. Based in the United States, this full-service global Contract Research Organization (CRO) partners with biotech companies primarily in the US and China.
With a proven track record, D2V Clinical leverages over 20 years of industry leadership to advance biopharmaceutical value creation, helping eradicate diseases that have unmet medical needs. Their robust network of principal investigators and access to electronic medical records facilitate expedited patient enrollment, smoothing the road to efficient clinical studies.
Their recent $10.00M Series A investment on 23 August 2022, backed by notable investors like Delian Capital, Ming Bioventures, and Suzhou Industrial Park Hongfeng Venture Capital, underscores market confidence in their mission. As they enhance drug development through strategic insights and risk management, D2V Clinical emerges as a crucial ally in accelerating breakthrough treatments to market.
